Endogenous galactose formation in galactose-1-phosphate uridyltransferase deficiency

Archives of Physiology and Biochemistry

Volumn 120, Issue 5, 2014, Pages 228-239

  Schadewaldt, Peter ^a   Kamalanathan, Loganathan ^a   Hammen, Hans Werner ^a   Kotzka, Jorg ^a   Wendel, Udo ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Carbon isotopes; Galactitol; Galactonic acid; Galactosaemia; Galactose; Galactose 1 phosphate uridyltransferase; Human; Metabolism

Indexed keywords

GALACTOSE; GALACTOSE 1 PHOSPHATE URIDYLYLTRANSFERASE;

ADOLESCENT; ADULT; BIOSYNTHESIS; BLOOD; CHILD; DEFICIENCY; ENZYMOLOGY; ERYTHROCYTE; FEMALE; GALACTOSEMIA; HUMAN; MALE; METABOLISM; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; FEMALE; GALACTOSE; GALACTOSEMIAS; HUMANS; MALE; UTP-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; YOUNG ADULT;

EID: 84908575439     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2014.962547     Document Type: Conference Paper

References (39)

1. Allsop JR, Wolfe RR, Burke JF. (1978). Tracer priming the bicarbonate pool. J Appl Physiol, 45: 137-9.
2. Berry GT, Moate PJ, Reynolds RA, et al. (2004). The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol Genet Metab, 81: 22-30.
3. Berry GT, Nissim I, Lin Z, et al. (1995). Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet, 346: 1073-4.
4. Bosch AM, Prick L, Ter Horst NM, et al. (2002). Oral galactose loading does not affect clinical or biochemical parameters in classical galactosemia. J Inherit Metab Dis, 25: 129.
5. Brandt I, Reinken L. (1988). The growth rate of healthy children in the first 16 years: Bonn-Dortmund longitudinal developmental study. Klin Pädiatr, 200: 451-6.
6. Calderon FR, Phansalkar AR, Crockett DK, et al. (2007). Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene. Hum Mutat, 28: 939-43. Database URL: http://www.arup.utah.edu/database/GALT/GALT-welcome.php; [last accessed 7 Jul 2014].
7. Christacos NC, Fridovich-Keil JL. (2002). Impact of patients mutations on heterodimer formation and function in human galactose-1-phosphate uridyltransferase. Mol Genet Metab, 76: 319-26.
8. Coss KP, Byrne JC, Coman DJ, et al. (2012). IgG N-glycans as potential biomarkers for determining galactose tolerance in Classical Galactosaemia. Mol Genet Metab, 105: 212-20.
9. Elsas LJ, Langley S, Steele E, et al. (1995). Galactosemia: A strategy to identify new biochemical phenotypes and molecular genotypes. Am J Hum Genet, 56: 630-9.
10. Elsevier JP, Fridovich-Keil JL. (1996). The Q188R mutation in human galactose-1-phosphate uridyltransferase acts as a partial dominant negative. J Biol Chem, 271: 32002-7.
11. Elsevier JP, Wells L, Quimby BB, Fridovich-Keil JL. (1996). Heterodimer formation and activity in the human enzyme galactose- 1-phosphate uridyltransferase. Proc Natl Acad Sci USA, 93: 7166-71.
12. Fridovich-Keil JL, Jinks-Robertson S. (1993). A yeast expression system for human galactose-1-phosphate uridyltransferase. Proc Natl Acad Sci USA, 90: 398-402.
13. Fridovich-Keil JL, Langley SD, Mazur LA, et al. (1995). Identification and functional analysis of three distinct mutations in the human galactose-1-phosphate uridyltransferase gene associated with galactosemia in a single family. Am J Hum Genet, 56: 640-6.
14. Geigy. (1977). Wissenschaftliche Tabellen Geigy: Einheiten im Messwesen, Korperflussigkeiten, Organe, Energiehaushalt, Ernahrung. 8th edn. Basel, Switzerland: Ciba-Geigy Ltd. p 213.
15. Gitzelmann R, Steinmann B. (1984). Galactosaemia: How does longterm treatment change the outcome? Enzyme, 32: 37-46.
16. Haycock G, Schwartz G, Wisotsky D. (1978). Geometric method for measuring body surface area: A height-weight formula validated in infants, children and adults. J Pediatr, 93: 62-6.
17. Henderson JM, Kutner MH, Bain RP. (1982). First-order clearance of plasma galactose: The effect of liver disease. Gastroenterology, 83: 1090-6.
18. Holton JB, Walter JH, Tyfield LA. (2001). Galactosemia. In: Scriver CR, Beaudet AL, Sly W, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1553-87.
19. Kamalanathan L, Hammen H-W, Wendel U, Schadewaldt P. (2003). Endogenous galactose release in classical galactosemia: Influence of residual enzyme activity. J Inherit Metab Dis, 26: 125.
20. Lehrfeld J. (1985). G.L.C. determination of aldonic acids as acetylated aldonamides. Carbohydr Res, 135: 179-85.
21. Ning C, Fenn PT, Blair IA, et al. (2000). Apparent galactose appearance rate in human galactosemia based on plasma [13C]galactose isotopic enrichment. Mol Genet Metab, 70: 261-71.
22. Reichardt JKV, Belmont JW, Levy HL, Woo SLC. (1992). Characterization of two missense mutations in human galactose-1-phosphate uridyltransferase: Different molecular mechanisms for galactosemia. Genomics, 12: 596-600.
23. Reichardt JKV, Novelli G, Dallapiccola B. (1993). Molecular characterization of the H319Q galactosemia mutation. Hum Mol Genet, 2: 325-6.
24. Reichardt JKV, Woo SLC. (1991). Molecular basis of galactosemia: Mutations and polymorphisms in the gene encoding human galactose- 1-phosphate uridyltransferase. Proc Natl Acad Sci USA, 88: 2633-7.
25. Riehman K, Crews C, Fridovich-Keil JL. (2001). Relationship between genotype, activity and galactose sensitivity in yeast expressing patient alleles of human galactose-1-phosphate uridyltransferase. J Biol Chem, 276: 10634-40.
26. Roe TF, Hallat JG, Donnell GN, Ng WG. (1971). Childbearing by a galactosemic woman. J Pediatr, 78: 1026-30.
27. 13C enrichment of D-galactose in human plasma. Clin Chem, 46: 612-19.
28. Schadewaldt P, Kamalanathan L, Hammen H-W, Wendel U. (2003). Stable isotope dilution analysis of galactose metabolites in human erythrocytes. Rapid Commun Mass Spectrom, 17: 2833-8.
29. Schadewaldt P, Kamalanathan L, Hammen H-W, Wendel U. (2004). Age dependence of endogenous galactose formation in Q188R-homozygous galactosemic patients. Mol Genet Metab, 81: 31-44.
30. 2 breath tests: Methodology and fundamental considerations. J Lab Clin Med, 90: 412-21.
31. Schweitzer S, Shin Y, Jakobs C, Brodehl J. (1993). Long-term outcome in 134 patients with galactosaemia. Eur J Pediatr, 152: 36-43.
32. Segal S, Rogers S, Holtzapple PG. (1971). Liver galactose-1-phosphate uridyl transferase: Activity in normal and galactosemic subjects. J Clin Invest, 50: 500-6.
33. Shin YS. (1991). Galactose metabolites and disorders of galactose metabolism. In: Hommes FA, ed. Techniques in Diagnostic Human Biochemical Genetics. New York: Wiley-Liss, 267-83.
34. 14C]pyruvate in normal, acromegalic, and HGH treated human subjects. Acta Endocrinol, 65: 155-69.
35. Van Calcar SC, Bernstein LE, Rohr FJ, et al. (2014). A re-evaluation of life-long severe galactose restriction for the nutrition management of classic galactosemia. Mol Genet Metab, 112: 191-7.
36. Waggoner DD, Buist NRM, Donnell GN. (1990). Long-term prognosis in galactosaemia: Results of a survey of 350 cases. J Inherit Metab Dis, 13: 802-18.
37. Wahlefeld AW, Siedel J. (1985). Creatine and creatinine. In: Bergmeyer HU, ed. Methods in Enzymatic Analysis, Vol. VII. Weinheim: Verlag Chemie, 488-506.
38. Walter JH, Collins JE, Leonard JV. (1999). Recommendations for the management of galactosaemia. Arch Dis Child, 80: 93-6.
39. Xu YK, Kaufman FR, Donell GN, Ng WG. (1995). Radiochemical assay of minute quantities of galactose-1-phoshate uridyltransferase activity in erythrocytes and leucocytes of galactosemic patients. Clin Chim Acta, 235: 125-36.